Myocarditis

Czech version

Authors: J. Vítovec; J. Lipoldová
Authors‘ workplace: I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
Published in: Vnitř Lék 2009; 55(9): 702-709
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Overview

Myocarditis is a disorder with a wide range of symptoms spanning from light breathlessness or chest pain, ceasing without specific treatment, through cardiogenic shock, requiring left ventricular assistance, to sudden death. Dilated cardiomyopathy with chronic cardiac failure might be the very consequence of the precedent myocarditis. Myocarditis is the most frequently caused by viral infections, less frequently by specific infections, toxic or hypersensitivity reactions to medicines, giant cell myocarditis or sarcoidosis. Prognosis and treatment differ according to the cause, clinical or haemodynamic signs inform decision-making on care provided by cardiology centres, including decisions on execution and interpretation of myocardial biopsy. The present overview aims to provide practical guidance on diagnosis and treatment of myocardial inflammation.

Key words:
myocarditis – aetiology – diagnosis – treatment – prognosis

Sources

1. Aretz HT, Billingham ME, Edwards WD et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1: 3–14.

2. Baughman KL. Diagnosis of Myocarditis: Death of Dallas Criteria. Circulation 2006; 113; 593–595.

3. Dec GW. Introduction to clinical myocarditis. In: Cooper LT (ed). Myocarditis: From Bench to Bedside. Totowa, NJ: Humana Press 2003: 257–282.

4. Lieberman EB, Hutchins GM, Herskowitz A et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991; 18: 1617–1626.

5. Tang Wai HW. Myocarditis. September 2, 2008. Available from: http://emedicine.medscape.com/article/156330-overview.

6. Rodriguez E, Ross RD. Myocarditis,Viral. Oct 9, 2008. Available from: http://emedicine.medscape.com/article/890740-overview.

7. Acosta AM, Santos-Buch CA. Autoimmune myocarditis induced by Trypanosoma cruzi. Circulation 1985; 71: 1255–1261.

8. Liu PP, Mason JW. Advances in the Understanding of Myocarditis. Circulation 2001; 104: 1076–1082.

9. Fairweather D, Kaya Z, Shellam GR et al. From Infection to Autoimmunity. J Autoimmun 2001; 16: 175–186.

10. Badorff C, Lee GH, Knowlton KU. Enteroviral Cardiomyopathy: Bad News for the Dystrophin-Glycoprotein Complex. Herz 2000; 25: 227–232.

11. Leipner C, Grün K, Borchers M et al. The Outcome of Coxsackievirus B3-(CVB3-) Induced Myocarditis is Influenced by the Cellular Immune Status. Herz 2000; 25: 245–248.

12. Yajima T, Knowlton KU. Viral Myocarditis: From the Perspective of the Virus. Circulation 2009; 119: 2615–2624.

13. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675–680.

14. Huang CH, Vallejo JG, Kollias G et al. Role of the innate immune system in acute viral myocarditis. Basic Res Cardiol 2009; 104: 228–237.

15. von Herrath MG, Oldstone MB. Virus-induced autoimmune disease. Curr Opin Immunol 1996; 8: 878–885.

16. Damås JK, Gullestad L, Aukrust P. Cytokines as new treatment targets in chronic heart failure. Curr Control Trials Cardiovasc Med 2001; 2: 271–277.

17. Hegarová M, Honsová E, Lodererová A et al. Zánětlivá kardiomyopatie: současné poznatky o etiopatogenezi, možnostech diagnostiky a léčby. Cor Vasa 2004; 46: 177–182.

18. Kvasnička J. Virová myokarditida. Kap Kardiol 2006; 8: 3–7.

19. Müllerová J, Novák M, Vítovec J. Myokarditidy. Kardiol Rev 2003; 5: 56–59.

20. Zeman K. Myokarditidy – editorial. Vnitř Lék 2005; 51: 17–19.

21. Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360: 1526–1538.

22. Pankuweit S, Portig I, Eckhardt H et al. Prevalence of Viral Genome in Endomyocardial Biopsies from Patients with Inflammatory Heart Muscle Disease. Herz 2000; 25: 221–226.

23. Davydova J, Pankuweit S, Crombach M et al. Detection of Viral and Bacterial Protein in Endomyocardial Biopsies of Patients with Inflammatory Heart Muscle Disease? Herz 2000; 25: 233–239.

24. Liu PP, Mason JW. Advances in the Understanding of Myocarditis. Circulation 2001; 104: 1076–1082.

25. Mahrholdt H, Goedecke C, Wagner A et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109: 1250–1258.

26. Gutberlet M, Spors B, Thoma T et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and asso-ciation with immunohistologically detected inflammation and viral persistence. Radiology 2008; 246: 401–409.

27. Wojnicz R, Nowalany-Kozielska E, Wodniecki J et al. Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J 1998; 19: 1564–1572.

28. Wu LA, Lapeyre AC 3rd, Cooper LT. Current Role of Endomyocardial Biopsy in the Management of Dilated Cardiomyopathy and Myocarditis. Mayo Clin Proc 2001; 76: 1030–1038.

29. Cooper LT, Baughman KL, Feldman AM et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the AHA, ACC, and ESC. Circulation 2007; 116: 2216–2233.

30. Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077–1084.

31. Brunerová L, Rychlík I, Bartáková H et al. Akutní myokarditida manifestující se obrazem transmurálního infarktu myokardu provázená akutním renálním selháním. Vnitř Lék 2005; 51: 106–112.

32. Maron BJ, Ister JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994; 24: 880–885.

33. Moloney ED, Egan JJ, Kelly P et al. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant 2005; 24: 1103–1110.

34. Deonarain R, Cerullo D, Fuse K et al. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 2004; 110: 3540–3543.

35. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C et al. Randomized, Placebo-Controlled Study for Immunosuppressive Treatment of Inflammatory Dilated Cardiomyopathy. Two-Year Follow-Up Results. Circulation 2001; 104: 39–45.

36. Hufnagel G, Pankuweit S, Richter A et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results. Herz 2000; 25: 279–285.

37. Staudt A, Hummel A, Ruppert J et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J 2006; 152: 712.e1–712.e6.

38. Mason JW, O’Connell JB, Herskowitz Aet al. A Clinical Trial of Immunosuppressive Therapy for Myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333: 269–275.

39. Nishio R, Shioi T, Sasayama S et al. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol 2003; 41: 340–345.

40. Nishii M, Inomata T, Niwano H et al. Beta-2-adrenergic agonists suppress rat autoimmune myocarditis: potential role of beta2-adrenergic stimulants as new therapeutic agents for myocarditis. Circulation 2006; 114: 936–944.

41. Kuchynka P, Paleček T, Šimek S et al. Zánětlivá kardiomyopatie: aktuální pohled na diagnostiku a léčbu. Cor Vasa 2009; 51: 32–37.